kpvi1d
FDA OK's Ozempic To Protect Kidneys in Type 2 Diabetes Patients
Type 2 diabetes is a leading cause of chronic kidney disease, which affects more than 1 in 7 U.S. adults. The new approval ...
FiercePharma1d
Hims & Hers tackles pharma industry drug pricing in Super Bowl ad for compounded GLP-1s
Telehealth company Hims & Hers is playing offense in a new commercial slated to air during the Super Bowl next month. | Telehealth company Hims & Hers is playing offense in a new commercial slated to ...
Hims & Hers: Potential Risks Ahead, But Shorting May Be Premature
Hims & Hers may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings. Learn why HIMS stock is ...
ENDPOINTS NEWS2d
Semaglu­tide, tirzepatide com­pounder hit with FDA warn­ing let­ter
Compounding facility ProRx Pharmacy Network has received an FDA warning letter over issues with its semaglutide and ...
Hims & Hers to Advertise Weight-Loss Shots at the Super Bowl
Telehealth provider will make its big game debut as the semaglutide shortage continues to sustain the firm’s lower-priced ...
OneSource sees surge in demand as semaglutide patents near expiry
The company emphasised that it is ready to meet the growing demand for drug-device combinations and biologics, with ...
News 6 WKMG6d
Weight loss drugs help users lose weight, change spending habits, studies show
Dr. George Carroll runs BeSlimMD, a private weight loss clinic in Maitland. He has been helping patients lose weight for more ...